Competing interests
Johnson & Johnson.
EMA
NZ, LC, TD, WCD, VP, D-JF, and RL are employees of Janssen Research & Development, LLC or Janssen Research & Development Belgium, and all are stockholders of Johnson & Johnson. RLM was an employee of Janssen Research & Development, LLC at the time this work was conducted. In the last 12 months. GS has provided consulting services to Ancora, Aptinyx, Axsome Therapeutics, Biohaven Pharmaceuticals, Bristol-Myers Squibb, Clexio Biosciences, Denovo Biopharma, EMA Wellness, Engrail, Gilgamesh, Freedom Biosciences, Intra-Cellular Therapies, Janssen, miCure Therapeutics, Merck, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Perception Neuroscience, Praxis, Sage Pharmaceuticals, Seelos Pharmaceuticals, and XW Labs. He has received funds for contracted research from Janssen Pharmaceuticals, Merck, and Usona Institute. He holds equity in Biohaven Pharmaceuticals and has received royalties paid from patent licenses with Biohaven Pharmaceuticals. His employer, Yale University, has a financial relationship with Janssen Pharmaceuticals and may receive financial benefits from this relationship. STW has received contract funding for clinical trials from Sage Therapeutics, Oui Therapeutics, and Janssen (administered through Yale University). He has received consulting fees from Sage Therapeutics, Oui Therapeutics, and Janssen.